Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $61.11

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have received a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $61.11.

Several research firms recently issued reports on HALO. Wells Fargo & Company cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and upped their price target for the company from $58.00 to $62.00 in a report on Monday, October 7th. HC Wainwright restated a "buy" rating and set a $68.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday. JPMorgan Chase & Co. cut Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and lifted their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler raised their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a "neutral" rating in a research note on Monday, November 4th.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 10,000 shares of the business's stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $52.58, for a total transaction of $525,800.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares of the company's stock, valued at approximately $35,583,199.52. The trade was a 1.46 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 30,000 shares of company stock valued at $1,621,800. Corporate insiders own 2.40% of the company's stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC boosted its holdings in Halozyme Therapeutics by 15.2% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 11,771 shares of the biopharmaceutical company's stock valued at $616,000 after purchasing an additional 1,554 shares during the period. Envestnet Portfolio Solutions Inc. lifted its position in shares of Halozyme Therapeutics by 21.3% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 11,467 shares of the biopharmaceutical company's stock worth $600,000 after acquiring an additional 2,016 shares during the period. Raymond James & Associates lifted its position in Halozyme Therapeutics by 51.8% in the second quarter. Raymond James & Associates now owns 146,261 shares of the biopharmaceutical company's stock worth $7,658,000 after purchasing an additional 49,923 shares during the period. Fifth Third Bancorp boosted its stake in Halozyme Therapeutics by 2.4% during the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 261 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC bought a new stake in Halozyme Therapeutics in the 2nd quarter valued at $225,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Up 1.0 %

Shares of NASDAQ:HALO traded up $0.48 during midday trading on Thursday, hitting $47.32. 1,754,666 shares of the company's stock traded hands, compared to its average volume of 1,365,213. The company has a market cap of $6.02 billion, a PE ratio of 15.67, a P/E/G ratio of 0.43 and a beta of 1.23. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53. The firm's fifty day moving average price is $51.12 and its two-hundred day moving average price is $54.09.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.